Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
28.48 ^CNY	-2.83%		-4.53%	-45.30%

Apr. 26	Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	China Stocks Fall Ahead of March Economic Data Release	MT

Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023

August 30, 2023 at 08:56 am EDT

Hinova Pharmaceuticals Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was CNY 165.2 million compared to CNY 147.87 million a year ago. Basic loss per share from continuing operations was CNY 1.67 compared to CNY 1.74 a year ago.

Latest news about Hinova Pharmaceuticals Inc.

Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
China Stocks Fall Ahead of March Economic Data Release	Apr. 08	MT
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%	Apr. 08	MT
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets	Feb. 23	MT
Hinova Pharmaceuticals Gets US FDA's Nod to Conduct Phase II Clinical Trial on HP501 Tablets	Dec. 07	MT
Hinova Pharmaceuticals Gets Nod to Test Prostate Cancer Drug	Nov. 03	MT
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hinova Pharmaceuticals to Resubmit Application for Deuterated Enzalutamide Soft Capsules	23-10-23	MT
Hinova Pharmaceuticals Inc.(XSSC:688302) added to S&P Global BMI Index	23-09-18	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange Composite Index	23-04-13	CI
Hinova Pharmaceuticals Inc.(SHSE:688302) added to Shanghai Stock Exchange A Share Index	23-04-13	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Hinova Pharma Gets Regulatory Nod for Anti-Tumor Drug Trial	23-02-10	MT
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment	23-02-06	CI
Hinova Pharmaceuticals Gets FDA's Nod to Hold Trial on Anti-Cancer Drug; Shares Jump 5%	23-02-01	MT
MagicRNA announced that it has received $2.900000 million in funding from Goldport Capital, Shenzhen Credit Guarantee Group Co., Ltd, Hinova Pharmaceuticals Inc., NLPE, Shenzhen Hongtao Fund Management Co., Ltd. and other investors.	22-12-29	CI
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit	22-10-28	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Hinova Pharmaceuticals Inc. announced that it has received $147.3 million in funding from a group of investors	20-10-01	CI
Hinova Pharmaceuticals Inc. announced that it expects to receive $5.000006 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.	19-12-19	CI

Chart Hinova Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Hinova Pharmaceuticals Inc is a Chinese company mainly engaged in the research and development of innovative drugs for critical illnesses. The Company focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The Company's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The Company has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The Company conducts clinical tests in domestic and overseas areas.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.48

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HINOVA PHARMACEUTICALS INC.	-45.30%	401M
MODERNA, INC.	+55.70%	55.7B
LONZA GROUP AG	+41.08%	39.91B
IQVIA HOLDINGS INC.	-5.39%	39.57B
CELLTRION, INC.	-5.56%	28.16B
ICON PUBLIC LIMITED COMPANY	+16.46%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	18.94B
MEDPACE HOLDINGS, INC.	+33.03%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.85%	12.12B
BIO-TECHNE CORPORATION	+2.72%	12.12B

Other Biotechnology & Medical Research